Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Subviral Agents01:29

Subviral Agents

556
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
556
Air-entraining Agents01:27

Air-entraining Agents

270
Air-entraining agents improve the durability and workability of concrete in climates with frequent freezing and thawing. These agents prevent cracks by introducing small air bubbles into the mix, creating spaces accommodating water expansion when temperatures drop. The air-entraining agents lower the surface tension of water, forming stable, small air bubbles. This method is more effective than having accidental large voids, as the intentional, smaller, and evenly distributed air voids improve...
270
Masking and Demasking Agents01:19

Masking and Demasking Agents

3.6K
EDTA titrations may necessitate masking and demasking agents to temporarily protect a particular metal ion in a mixture from the EDTA reaction. These agents facilitate the sequential analysis of the metal ions by forming stable complexes with some—but not all—metal ions during certain steps.
There are many masking agents, such as cyanide, fluoride, triethanolamine, thiourea, and 2,3-bis(sulfanyl)propan-1-ol (formerly 2,3-dimercapto-1-propanol), with the masking agent chosen based on...
3.6K
Spasmolytic Agents: Chemical Classification01:29

Spasmolytic Agents: Chemical Classification

1.3K
Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
1.3K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

655
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
655
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

1.6K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Bipyridine and Phenanthroline Incorporation into the Macropa Scaffold on Ba(II)/Ra(II) Chelation.

Inorganic chemistry·2026
Same author

Liver transplantation in unresectable intrahepatic cholangiocarcinoma following neoadjuvant chemotherapy and SIRT.

JHEP reports : innovation in hepatology·2026
Same author

Health-related quality of life in biliary tract cancer clinical trials. The current state and future directions.

ESMO gastrointestinal oncology·2026
Same author

Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial).

Immuno-oncology technology·2026
Same author

Reply to letter comments on: Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, phase III umbrella trial (SAFIR-ABC10-Precision Medicine).

ESMO open·2025
Same author

[<sup>90</sup>Y]Y-L4-Lipo/ ethyl esters of Iodized fatty acids of poppy seed oil (lipiodol<sup>®</sup> ultra-fluid), a new TARE formulation, designed from a lipophilic ligand for stability and safety.

EJNMMI radiopharmacy and chemistry·2025

Related Experiment Video

Updated: Jan 30, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.2K

Transarterial Radioembolization (TARE) Agents beyond 90Y-Microspheres.

C Bouvry1,2, X Palard1,3, J Edeline1,4

  • 1Comprehensive Cancer Centre Eugène Marquis, 35042 Rennes, France.

Biomed Research International
|January 29, 2019
PubMed
Summary

Transarterial radioembolization (TARE) offers promising results for liver tumors like hepatocellular carcinoma (HCC). This review explores alternative, potentially more accessible TARE technologies for treating advanced liver malignancies.

More Related Videos

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

9.9K
Fabrication of Polymer Microspheres for Optical Resonator and Laser Applications
08:06

Fabrication of Polymer Microspheres for Optical Resonator and Laser Applications

Published on: June 2, 2017

14.6K

Related Experiment Videos

Last Updated: Jan 30, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.2K
Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

9.9K
Fabrication of Polymer Microspheres for Optical Resonator and Laser Applications
08:06

Fabrication of Polymer Microspheres for Optical Resonator and Laser Applications

Published on: June 2, 2017

14.6K

Area of Science:

  • Hepatobiliary oncology
  • Interventional radiology
  • Nuclear medicine

Background:

  • Liver malignancies, including hepatocellular carcinoma (HCC) and cholangiocarcinoma, are leading causes of cancer death with rising incidence.
  • HCC often has a poor prognosis due to underlying liver disease and late diagnosis, limiting curative surgical options to 20-30% of patients.
  • Internal radionuclide therapy, specifically transarterial radioembolization (TARE), presents an attractive treatment for intermediate to advanced liver tumors.

Purpose of the Study:

  • To review alternative transarterial radioembolization (TARE) technologies currently under development and investigation in clinical trials.
  • To focus on novel TARE approaches for treating hepatocellular carcinoma (HCC).

Main Methods:

  • Review of current clinical trial data on emerging TARE technologies.
  • Analysis of alternative radiolabeled embolizing agents and delivery systems.
  • Comparative assessment of novel TARE approaches against established methods.

Main Results:

  • Established TARE using 90Y-loaded microspheres shows promising outcomes but faces limitations due to high cost and limited availability.
  • Several alternative TARE technologies are in development, aiming to improve accessibility and potentially efficacy.
  • Ongoing clinical trials are evaluating the safety and effectiveness of these novel TARE approaches for liver tumors, particularly HCC.

Conclusions:

  • While 90Y-TARE is an established treatment, its cost and availability restrict widespread use.
  • Development of alternative TARE technologies is crucial to expand treatment options for patients with liver malignancies, especially HCC.
  • Further research and clinical trials are needed to validate the efficacy and cost-effectiveness of these emerging TARE alternatives.